Limits...
Predicting subtypes of thymic epithelial tumors using CT: new perspective based on a comprehensive analysis of 216 patients.

Hu YC, Wu L, Yan LF, Wang W, Wang SM, Chen BY, Li GF, Zhang B, Cui GB - Sci Rep (2014)

Bottom Line: Current CT diagnostic parameters could not effectively achieve this goal.Findings from this study support role of studied parameters of CT manifestations in predicting the low and high risk stages of TETs.These findings provide empirical evidence for incorporating these parameters in clinical practice for identifying TETs stage before operation, if validated in additional studies.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China.

ABSTRACT
It is highly necessary to identify low versus high risk thymic epithelial tumors (TETs) before operation to guide optimal treatment strategies. Current CT diagnostic parameters could not effectively achieve this goal. We evaluated three parameters of CT scan in a cohort of 216 TETs patients. Parameters of contrast enhancement, risk of aggressiveness, and nodule with fibrous septum were evaluated in low (A, AB) versus high risk (B1, B2, B3 and thymic carcinoma) TETs. Grade of contrast enhancement showed predictive value in classifying low and high risk TETs well. A maximal contrast-enhanced range of 25.5 HU could produce 78.8% sensitivity and 68.5% specificity in determining low risk subtypes. Additionally, risk of aggressiveness parameter was demonstrated to be associated with TETs subtype (r = 0.801, P < 0.001) and may add confidence in determining low versus high risk subtypes. Furthermore, multiple nodule with fibrous septum could suggest subtype AB. Findings from this study support role of studied parameters of CT manifestations in predicting the low and high risk stages of TETs. These findings provide empirical evidence for incorporating these parameters in clinical practice for identifying TETs stage before operation, if validated in additional studies.

Show MeSH

Related in: MedlinePlus

The receiver-operating-characteristic (ROC) curve describing the diagnostic performance of the maximal contrast-enhanced range (CEmax) to identify the low risk (A, AB) from high risk (B1, B2, B3 and thymic carcinoma) subtypes of TETs.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4225535&req=5

f2: The receiver-operating-characteristic (ROC) curve describing the diagnostic performance of the maximal contrast-enhanced range (CEmax) to identify the low risk (A, AB) from high risk (B1, B2, B3 and thymic carcinoma) subtypes of TETs.

Mentions: Figure 2 demonstrated the receiver operating characteristic (ROC) curve for the diagnostic performance of the maximal contrast-enhanced range (CEmax) in identifying the low from high risk TETs. The area under the curve (AUC) was 0.80 (95% CI, 0.71 to 0.89). And the best cutoff point for CEmax is at 25.5 HU, when the sensitivity and specificity for identifying low risk subtypes being 78.8% and 68.5%, respectively (Figure 2).


Predicting subtypes of thymic epithelial tumors using CT: new perspective based on a comprehensive analysis of 216 patients.

Hu YC, Wu L, Yan LF, Wang W, Wang SM, Chen BY, Li GF, Zhang B, Cui GB - Sci Rep (2014)

The receiver-operating-characteristic (ROC) curve describing the diagnostic performance of the maximal contrast-enhanced range (CEmax) to identify the low risk (A, AB) from high risk (B1, B2, B3 and thymic carcinoma) subtypes of TETs.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4225535&req=5

f2: The receiver-operating-characteristic (ROC) curve describing the diagnostic performance of the maximal contrast-enhanced range (CEmax) to identify the low risk (A, AB) from high risk (B1, B2, B3 and thymic carcinoma) subtypes of TETs.
Mentions: Figure 2 demonstrated the receiver operating characteristic (ROC) curve for the diagnostic performance of the maximal contrast-enhanced range (CEmax) in identifying the low from high risk TETs. The area under the curve (AUC) was 0.80 (95% CI, 0.71 to 0.89). And the best cutoff point for CEmax is at 25.5 HU, when the sensitivity and specificity for identifying low risk subtypes being 78.8% and 68.5%, respectively (Figure 2).

Bottom Line: Current CT diagnostic parameters could not effectively achieve this goal.Findings from this study support role of studied parameters of CT manifestations in predicting the low and high risk stages of TETs.These findings provide empirical evidence for incorporating these parameters in clinical practice for identifying TETs stage before operation, if validated in additional studies.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China.

ABSTRACT
It is highly necessary to identify low versus high risk thymic epithelial tumors (TETs) before operation to guide optimal treatment strategies. Current CT diagnostic parameters could not effectively achieve this goal. We evaluated three parameters of CT scan in a cohort of 216 TETs patients. Parameters of contrast enhancement, risk of aggressiveness, and nodule with fibrous septum were evaluated in low (A, AB) versus high risk (B1, B2, B3 and thymic carcinoma) TETs. Grade of contrast enhancement showed predictive value in classifying low and high risk TETs well. A maximal contrast-enhanced range of 25.5 HU could produce 78.8% sensitivity and 68.5% specificity in determining low risk subtypes. Additionally, risk of aggressiveness parameter was demonstrated to be associated with TETs subtype (r = 0.801, P < 0.001) and may add confidence in determining low versus high risk subtypes. Furthermore, multiple nodule with fibrous septum could suggest subtype AB. Findings from this study support role of studied parameters of CT manifestations in predicting the low and high risk stages of TETs. These findings provide empirical evidence for incorporating these parameters in clinical practice for identifying TETs stage before operation, if validated in additional studies.

Show MeSH
Related in: MedlinePlus